Evidence map›Paper›PMID 39330019›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

The Relationship between D'Amico and ISUP Risk Classifications and

Ozge Ulas Babacan, Zekiye Hasbek, Kerim Seker

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Multimodal integration of [Frontiers in oncology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ozge Ulas BabacanDepartment of Nuclear Medicine, School of Medicine, Tokat Gaziosmanpasa University, 60250 Tokat, Turkey.
Zekiye HasbekDepartment of Nuclear Medicine, School of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Turkey.
Kerim SekerDepartment of Nuclear Medicine, School of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Turkey.ORCID 0000-0003-1683-1776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to evaluate the relationship between pathological and clinical risk classifications in newly diagnosed prostate cancer patients, and

methodA total of 203 patients who were diagnosed with prostate cancer between 2019 and 2023, who had not yet received treatment and who underwent

resultsThere was a substantial correlation between D'Amico risk classification, Gleason score, ISUP classification, and the presence or absence of metastasis (

conclusionOur study showed that

Indexed as

Gallium IsotopesGallium RadioisotopesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overEdetic AcidHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProstate-Specific AntigenRisk AssessmentEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesProstate-Specific Antigen68Ga-PSMA PET/CTD’Amico risk classificationprostate cancer

Identifiers

PMID39330019
PMCPMC11430665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.